Advances in systemic targeted therapy and immunotherapy have dramatically improved outcome at least in some types of solid cancer. However, metastasis to the central nervous system remains a major diagnostic and therapeutic challenge, notably in long-term survivors with cancers.
Hörsaal Nord USZ & hybrid
25.01.2024
9.00 a.m. - 5.00 p.m.
Here we invite you to our 5th Zurich Brain Metastasis Symposium that will provide state-of-the-art presentations on current and future diagnostic and therapeutic approaches for patients with brain and leptomeningeal metastasis.
| 9.00 a.m. | Welcome Matthias Guckenberger, University Hospital Zurich Michael Weller, University Hospital Zurich |
|---|---|
| Session 1: Isabell Witzel | |
| 9.10 a.m. | Novel diagnostic approaches for CNS metastasis Pieter Wesseling, Amsterdam University Medical Centers, Amsterdam and Princess Máxima Center for Pediatric Oncology, Utecht, The Netherlands |
| 9.40 a.m. | Where do we stand with liquid biopsy in CNS metastases? Joan Seoane, Vall d’Hebron Institute of Oncology, Barcelona |
| 10.10 a.m. | Coffee Break |
| 10.30 a.m. | CSF studies in patients with CNS metastasis Adrienne Boire, Memorial Sloan Kettering Cancer Center, New York |
| 11.00 a.m. | Markers of response or hyperprogression to immune checkpoint inhibition Mitchell Levesque, University Hospital Zurich |
| Session 2: Nicolaus Andratschke | |
| 11.30 a.m. | New Challenges and opportunities for neurosurgeons in the management of brain metastasis Marian Neidert, Cantonal Hospital St. Gallen |
| 12.00 p.m. | New challenges and opportunities for Radiation Oncology in the management of brain metastasis Guiseppe Minniti, University La Sapienza, Rome |
| 12.30 p.m. | Lunch Break |
| 1.30 p.m. | Controversies from the CNS Metastasis Guideline process: screening, timing of radiotherapy, intrathecal pharmacotherapy Matthias Preusser, University Hospital Vienna |
| 2.00 p.m. | CNS trials at the Comprehensive Cancer Center Zurich Emilie Le Rhun, University Hospital Zurich |
| 2.15 p.m. | Pharmacoscopy for CNS metastasis Berend Snijder, ETH Zurich |
| Session 3: Andreas Wicki | |
| 2.30 p.m. | Blood brain barrier and phrmacokinetic and phase 0 studies Dieta Brandsma, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam |
| 3.00 p.m. | Assessing response in CNS metastases trials: the RANO perspective Lakshmi Nayak, Harvard University, Boston |
| 3.30 p.m. | Coffee Break |
| 3.50 p.m. | How to integrate brain metastasis into clinical trials: lessons from melanoma Reinhard Dummer, University Hospital Zurich |
| Keynote Lecture: Michael Weller | |
| 4.20 p.m. | Neoadjuvant immunotherapy: a perspective and a vision Alexander Eggermont, Prinses Máxima Centrum voor Kinderoncologie, Utrecht |
| 4.50 p.m. | Wrap-up |